To our knowledge, the present study is the first to reevaluate the association between YKL-40 expression and the clinical outcome of breast cancer patients by meta-analysis, demonstrating a inferior impact of elevated YKL-40 expression on the OS as well as DFS, which suggests its prognostic significance as a potentially serviceable biomarker. Here, CHI3L1 is linked to breast carcinoma.